This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Source of effectiveness data
The effectiveness data were derived from actual data within a review/synthesis of completed studies.
Modelling
Two models were used, and the results were compared. The purpose of the models was to estimate the number of infections averted as a result of access to a SEP for the study population. The first model was a simple formula using the absolute risk difference between access to a SEP and the lack of a SEP. The second model was a simplified circulation model. This estimated the decrease in HIV incidence in a population as a result of potentially infectious needles being removed from circulation among IDUs. To estimate the number of HIV infections averted, this was then applied to the projected number of SEP clients who would contract HIV in the absence of SEP. 
Outcomes assessed in the review

Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The effectiveness data in the first model were derived from only one study. A further three studies provided the effectiveness data in the second model.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The results were as follows:
the prevalence of HIV in the study population was 39.5% in New York City and 26.5% in Rochester; the attendance rate for SEP clients was 48.3%; the reduction in HIV incidence per 100 person-years at risk as a result of SEP was 3.35 (95% confidence interval: 1.29
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Measure of benefits used in the economic analysis
The benefit measure used was the number of HIV infections averted. A secondary analysis was also carried out, which used an estimate of the long-term costs of treatment saved because of an HIV infection averted. The costs of HIV treatment were discounted at 3% in the base-case analysis.
Direct costs
The resources and the costs were not reported separately. The direct costs were calculated to include the costs of the syringe exchange programmes, 'fringe' benefits and ancillary services provided to clients. In-kind and donated services were also included. Discounting was not applicable since the costs were incurred over a one-year period. Prices relate to 1996 and 1997 but a single price year was not stated.
Statistical analysis of costs
No statistical analysis was undertaken.
Indirect Costs
The analysis was stated to have been conducted from a societal perspective but no indirect costs of lost productivity were measured. (Correspondence with the author, subsequent to this abstract being written, indicates that this was due to the fact that participant costs were lacking).
Currency
US dollars ($).
Sensitivity analysis
A one-way sensitivity analysis was carried out on the HIV incidence among non-SEP users to allow for variability in data. A one-way sensitivity analysis was also conducted on the estimated number of shared injections per IDU per year, depending on the risk behaviour of different groups, to allow for the generalisability of the results.
